Record dengue numbers have a way of focusing attention. WHO reported 14.6 million dengue cases in 2024, the highest annual total on record, across more than 100 countries. Into that context steps Mosqitter, a Pennsylvania-based startup converting its chemical-free mosquito traps into a continent-spanning AI surveillance network aimed at governments, airports, and public-health agencies.
The company’s new platform, Febris, represents a meaningful pivot: from selling hardware that kills mosquitoes to building infrastructure that monitors them.
How a Bug Trap Became a Surveillance Node
Febris combines computer vision, environmental sensors, and entomologist review to assign confidence scores to captured mosquito species.
Captured insects are analyzed using neural-network software that cross-references external biological datasets. An entomologist then validates the result before a confidence score is assigned.
Layered on top of those detections, environmental data including weather, humidity, temperature, and atmospheric pressure may eventually support population forecasting. The system operates through a cloud-connected architecture that delivers dashboards, risk scoring, trend analysis, and alerts to institutional users.
One hard limit applies throughout: Mosqitter CEO Anastasiia Romanova told TechCrunch that Febris can identify the presence of a species associated with disease transmission, but it cannot confirm that any individual mosquito is infected with dengue or any other pathogen.
From 250 Devices to 5,000 Across Five Continents
Mosqitter’s deployment scale has grown roughly twenty-fold since 2022, with institutional customers now its primary target.
Across five continents, more than 5,000 devices now feed data into the platform, up from just over 250 when the company last received significant coverage in 2022. The product line spans two tiers: the Mini at $199, designed for residential and portable deployments, and the Grand at $1,999, built for larger public spaces, as reported by TechCrunch. Alongside other innovations in robotics and sensor tech, such as snake robots deployed for public-safety applications, distributed sensor networks are increasingly shaping how institutions respond to large-scale challenges.
Target customers for Febris include governments, public-health agencies, mosquito-control organizations, airports, municipalities, and universities. According to TechCrunch, Mosqitter is working with the U.K. Health Security Agency on deployments at Heathrow and Gatwick, where the system may help identify mosquito species introduced through international air travel.
By region, the company has tailored its approach: local manufacturing and sales in Brazil, direct-to-consumer channels in the United States, and partnerships with pest-control businesses in Greece.
The Business Model Behind the Bug Data
Hardware sales fund the current operation; Febris subscriptions and data services are where Mosqitter is betting its future.
Revenue today comes from hardware. The Febris layer is designed to generate recurring income through monitoring subscriptions, analytics, and data services sold to institutional clients.
Mosqitter told TechCrunch it had raised $1.9 million to date and was seeking $5 million in two tranches, starting with $1 million and followed by $4 million tied to Febris performance milestones. The company projects more than $1 million in total revenue for 2026 and more than $3.5 million in Febris-specific data revenue the following year; both figures are company projections and have not been independently verified.
What Validation Will Determine
Independent benchmarks for species-identification accuracy and false-positive rates have not been identified in published sources reviewed at the time of reporting.
No independent performance benchmarks for Febris species-identification accuracy or false-positive rates were identified in the sources reviewed. That gap matters: without verified field performance data, public-health agencies may have difficulty assessing whether the system meaningfully complements laboratory testing and conventional surveillance programs such as those maintained by the CDC and ECDC.
If third-party validation does emerge, continuous distributed monitoring at the scale Mosqitter describes could support earlier intervention decisions for airport biosecurity, municipal vector-control planning, and seasonal outbreak preparedness. These represent potential applications, not demonstrated outcomes. Whether the data holds up to that standard remains, for now, an open question.
